Verona Pharma PLC
(NASDAQ:VRNA)
$15.17
-0.19[-1.24%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$15.17
0[0.00%]
Open15.390Close-
Vol / Avg.192.477K / 297.854KMkt Cap1.206B
Day Range15.060 - 15.43052 Wk Range9.300 - 26.440

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$35.00

Lowest Price Target1

$30.00

Consensus Price Target1

$31.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Canaccord Genuity
  • Wedbush
  • Truist Securities
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Verona Pharma

All Ratings (22)

Upgrades (0)

Downgrades (0)

Initiations (2)

Q

What is the target price for Verona Pharma (VRNA)?

A

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.